Publication: European Pharmaceutical Review

First reported 8 hours ago - Updated 8 hours ago - 1 reports

Any Assay, Any Wavelength, Any Bandwidth with the new CLARIOstar® high performance microplate reader

Over the years, many different assays have been designed to work on many different microplate readers. As new techniques emerged, so did new microplate reader technology. The new CLARIOstar microplate reader from BMG LABTECH is the latest evolution in ... [Published European Pharmaceutical Review - 8 hours ago]

Entities: Assay, Bandwidth, Wavelength, Bertelsmann Music Group

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Amgen Inc

FDA approves Amgen?s XGEVA® (denosumab) for the treatment of giant cell tumor of bone

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone (GCTB) that is unresectable ... [Published European Pharmaceutical Review - Jun 14 2013]

Entities: XGEVA, Patient, Amgen Inc, FDA Food & Drug Administration, Denosumab

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

University of Colorado Denver

bioMérieux Industry celebrates the 10th anniversary of BioBall®

As world leader in the field of industrial microbiology control, bioMérieux is proud to celebrate the 10th anniversary of BioBall®, an innovative technology for quantitative microbiology Quality Control for the biopharmaceutical and cosmetic industri ... [Published European Pharmaceutical Review - Jun 12 2013]

Entities: bioMérieux SA, Microbiology, Biopharmaceutical, Microbiological, University of Colorado Denver

First reported Jun 10 2013 - Updated Jun 11 2013 - 1 reports

New four-strain influenza vaccine from Sanofi Pasteur now licensed by FDA for broad age range of children and adults

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, ... [Published European Pharmaceutical Review - Jun 10 2013]

Entities: Influenza, Vaccine, Fluzone Quadrivalent

First reported Jun 10 2013 - Updated Jun 11 2013 - 1 reports

Roche Holding AG

Roche?s RoACTEMRA approved in EU to treat children with rare form of arthritis

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency has approved RoACTEMRA to treat children with polyarticular juvenile idiopathic arthritis (PJIA), a rare, chronic and debilitating form of childhood arthritis. The medicine ... [Published European Pharmaceutical Review - Jun 10 2013]

Entities: Actemra, Patient, Roche Holding AG, Arthritis

First reported Jun 10 2013 - Updated Jun 10 2013 - 1 reports

Gilead Sciences Inc

Gilead announces U.S. FDA priority review designation for sofosbuvir for the treatment of hepatitis C

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s New Drug Application (NDA) for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment ... [Published European Pharmaceutical Review - Jun 10 2013]

Entities: Sofosbuvir, Gilead Sciences Inc, FDA Food & Drug Administration

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

GGC reports autism discovery

Researchers at the JC Self Research Institute of the (GGC), along with collaborators from Biolog, Inc. in California, have reported an important discovery in the understanding of autism which was published this week in Molecular Autism.The study, led ... [Published European Pharmaceutical Review - Jun 06 2013]

Entities: Autism, Biolog Inc, Metabolism, Amino Acid

First reported May 31 2013 - Updated May 31 2013 - 1 reports

Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week

. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for COPAXONE® (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE® ... [Published European Pharmaceutical Review - May 31 2013]

Entities: Copaxone, Teva Pharmaceutical Industries Ltd, FDA Food & Drug Administration, Multiple Sclerosis

First reported May 31 2013 - Updated May 31 2013 - 1 reports

Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes

Novo Nordisk today announced the submission to the European Medicines Agency of the marketing authorisation application for the approval of IDegLira, the combination product of insulin degludec (Tresiba®), the once-daily new-generation basal insulin analogue, ... [Published European Pharmaceutical Review - May 31 2013]

Entities: NOVO NORDISK A/S, Diabetes Type II, European Union, Insulin

First reported May 30 2013 - Updated May 30 2013 - 1 reports

Novo Nordisk supports new global commitment to fight noncommunicable diseases

This week, the World Health Assembly unanimously adopted a global action plan for the prevention and control of noncommunicable diseases (NCDs) 2013-2020. This is the first time member states of the World Health Organisation agree on a set of global targets ... [Published European Pharmaceutical Review - May 30 2013]

Entities: NOVO NORDISK A/S, Insulin, Diabetes

First reported May 28 2013 - Updated May 28 2013 - 1 reports

New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation

New findings from a pan-European online survey of 1,000 physicians have demonstrated that for over two thirds of physicians, preventing ischaemic stroke is the most important treatment goal for patients with atrial fibrillation (AF).1 Ischaemic stroke ... [Published European Pharmaceutical Review - May 28 2013]

Entities: Pradaxa, Atrial Fibrillation, Patient, Warfarin

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, ?Complications Combat?

Boehringer Ingelheim and have today launched an educational digital game for type 2 diabetes called Complications Combat. The game, available for desktop and iPad users, is designed to raise awareness of the many complications associated with type 2 diabetes ... [Published European Pharmaceutical Review - May 24 2013]

Entities: Diabetes Type II, Boehringer Ingelheim GmbH, Eli Lilly & Company, Diabetes

More Content

sort by: Date \| Relevance
Any Assay, Any Wavelength, Any Bandwidth with t... [Published European Pharmaceutical Review - 8 hours ago]
FDA approves Amgen?s XGEVA® (denosumab) for the... [Published European Pharmaceutical Review - Jun 14 2013]
bioMérieux Industry celebrates the 10th anniver... [Published European Pharmaceutical Review - Jun 12 2013]
New four-strain influenza vaccine from Sanofi P... [Published European Pharmaceutical Review - Jun 10 2013]
Roche?s RoACTEMRA approved in EU to treat child... [Published European Pharmaceutical Review - Jun 10 2013]
Gilead announces U.S. FDA priority review desig... [Published European Pharmaceutical Review - Jun 10 2013]
GGC reports autism discovery [Published European Pharmaceutical Review - Jun 06 2013]
Teva announces FDA acceptance of sNDA for a hig... [Published European Pharmaceutical Review - May 31 2013]
Novo Nordisk files for regulatory approval of I... [Published European Pharmaceutical Review - May 31 2013]
Novo Nordisk supports new global commitment to ... [Published European Pharmaceutical Review - May 30 2013]
New European survey highlights ischaemic stroke... [Published European Pharmaceutical Review - May 28 2013]
Boehringer Ingelheim and Eli Lilly & Company la... [Published European Pharmaceutical Review - May 24 2013]
Sanofi appoints David Loew, Senior Vice Preside... [Published European Pharmaceutical Review - May 24 2013]
Italy?s pharma market slump: revenue decline to... [Published European Pharmaceutical Review - May 21 2013]
Elan announces transactions: decisively transfo... [Published European Pharmaceutical Review - May 20 2013]
Verona Pharma: ATS Sunday poster presentations [Published European Pharmaceutical Review - May 20 2013]